Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DUKE Robotics Corp.USDR · Entity 7673 | Director | July 14, 2022 | July 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DUKE Robotics Corp.
Report date July 14, 2022 · Filed July 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,904,537 |
Reported balance
After 2022-07-14 transaction · row 1
1 source rowRow 1 · 2022-07-14 · Other · Disposed 157,094 · Balance 4,904,537 F1: On or about July 14, 2022, pursuant to the terms of a Settlement Agreement dated as of June 17, 2021 (the "Settlement Agreement"), by and among the Reporting Person, the Issuer, Afek Trading Kadosh and Razi Ltd., and Blackhawk Laboratories (the "Plaintiff"), the Reporting Person transferred 157,094 shares of common stock, for no consideration, to the Plaintiff pursuant to the Settlement Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: On or about July 14, 2022, pursuant to the terms of a Settlement Agreement dated as of June 17, 2021 (the "Settlement Agreement"), by and among the Reporting Person, the Issuer, Afek Trading Kadosh and Razi Ltd., and Blackhawk Laboratories (the "Plaintiff"), the Reporting Person transferred 157,094 shares of common stock, for no consideration, to the Plaintiff pursuant to the Settlement Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2022 Filed Jul 15, 2022 16:01 UTC | DUKE Robotics Corp. USDR · Entity 7673 | OtherCommon Stock | 157,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-039638 · ownership.xml · nonDerivative · entry 1 Aharon Sagiv · CIK 0001803076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,904,537 F1 · kind: On or about July 14, 2022, pursuant to the terms of a Settlement Agreement dated as of June 17, 2021 (the "Settlement Agreement"), by and among the Reporting Person, the Issuer, Afek Trading Kadosh and Razi Ltd., and Blackhawk Laboratories (the "Plaintiff"), the Reporting Person transferred 157,094 shares of common stock, for no consideration, to the Plaintiff pursuant to the Settlement Agreement. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 16:30 UTC | DUKE Robotics Corp. USDR · Entity 7673 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001213900-21-037064 · ownership.xml · derivative · entry 1 Aharon Sagiv · CIK 0001803076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2027-07-13 F1 · derivative.exercise_date: The options shall vest over a three year period, subject to the reporting person's continued service to the company, with 50% of the options to vest on the first anniversary of the grant date, and the balance of 50% of the options to vest in equal parts on the second and third anniversary of the grant date, respectively. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.